Hyphen Biomed

HYPHEN BioMed develops, manufactures and distributes in-vitro diagnostic and research reagents for thrombosis, hemostasis, fibrinolysis and autoimmune disorders. Its range includes global and routine tests, primary hemostasis and bleeding disorder assays, thrombophilia and anticoagulant monitoring tests, calibrators and controls, and auxiliary reagents. The company produces its main raw materials in-house and states that its diagnostic reagents are CE marked and 510(k) cleared.

Customers are hospital laboratories, research institutions and pharmaceutical companies, served directly and through international distributors. The company sells reagents in ready-to-use and freeze-dried formats for automated and manual applications.

HYPHEN BioMed was founded in January 1999 by Dr Jean Amiral and Anne Marie Vissac and joined the Sysmex group at the end of 2010. It is headquartered in Neuville-sur-Oise, in the Paris area, and is ISO 13485:2016 certified and MDSAP audited. The company states that it has over 100 employees, works with over 30 specialised distributors and offers over 500 products.

Product: In-vitro diagnostic and research reagents for coagulation, thrombosis, fibrinolysis and autoimmune disorder testing, including calibrators and controls.